Associate Principal Scientist - In Vivo Pharmacology

Proclinical
Nottingham, Nottinghamshire, United Kingdom
2 weeks ago
£50,000 – £500,000 pa

Salary

£50,000 – £500,000 pa

Seniority
Lead
Posted
5 Aug 2026 (2 weeks ago)

Ready to lead groundbreaking research that could transform the future of kidney disease treatment?

Proclinical is working alongside an internationally recognised drug discovery organisation who are seeking an experienced Associate Principal Scientist to provide scientific leadership across innovative preclinical discovery programmes focused on kidney disease, nephrology, chronic kidney disease, acute kidney injury, renal fibrosis and progressive renal disorders.

This is a senior scientific leadership opportunity for an experienced pharmacologist with expertise in renal disease biology and translational drug discovery. You will play a key role in advancing novel therapeutics from target validation through candidate selection while working closely with biotechnology and pharmaceutical partners developing next-generation treatments for kidney disease.

The Opportunity

Working within multidisciplinary drug discovery teams, you will be responsible for the design, delivery, and interpretation of pharmacology studies supporting programmes across:

Chronic Kidney Disease (CKD)

Acute Kidney Injury (AKI)

Diabetic Kidney Disease (DKD)

Diabetic Nephropathy

Renal Fibrosis

Glomerular Disease

Podocyte Biology

Proteinuria

Albuminuria

Tubulointerstitial Fibrosis

Kidney Inflammation

Fibrotic Kidney Disorders

Metabolic-Renal Disease

Cardio-Renal DiseaseYou will contribute to target validation, mechanism-of-action studies, translational biomarker strategies and efficacy assessment, supporting progression of novel therapeutics into development.

Key Responsibilities:

Lead and scientifically direct in vivo pharmacology programmes focused on renal and nephrology indications

Design and oversee studies utilising relevant disease models of:

CKD

AKI

Renal Fibrosis

Diabetic Kidney Disease (DKD)

Proteinuric Kidney Disease

Glomerulonephritis

Nephropathy

Kidney Inflammation

Progressive Renal Disease

Drive translational pharmacology strategies linking preclinical findings to clinical outcomes

Support target validation and mechanism-of-action studies across pathways implicated in:

Fibrosis

Inflammation

Immune-Mediated Kidney Disease

Metabolic Dysfunction

Tissue Remodelling

Renal Injury and Repair

Analyse and interpret efficacy, pharmacodynamic and biomarker data to guide programme decisions

Collaborate with medicinal chemistry, DMPK, translational science, biomarker and safety teams

Present scientific recommendations and project updates to external biotech and pharmaceutical clients

Mentor scientists and contribute to the development of innovative in vivo and translational capabilities

About You

Essential Experience

PhD in Pharmacology, Physiology, Nephrology, Biomedical Sciences or related discipline, or equivalent industry experience

Significant experience in in vivo pharmacology within pharmaceutical, biotechnology or CRO-based drug discovery environments

Strong expertise in renal disease biology and nephrology research

Experience working within one or more of the following areas:

Chronic Kidney Disease (CKD)

Acute Kidney Injury (AKI)

Diabetic Kidney Disease (DKD)

Diabetic Nephropathy

Renal Fibrosis

Kidney Inflammation

Glomerular Disease

Proteinuria

Albuminuria

Podocyte Dysfunction

Tubular Injury

Fibrotic Disorders

Proven ability to design, interpret and lead complex preclinical pharmacology studies

Experience influencing scientific strategy and programme progression decisions

Knowledge of UK regulations governing in vivo research

Excellent communication and stakeholder engagement skills Highly Desirable

Expertise in translational nephrology

Biomarker identification and validation

Renal functional endpoints including:

eGFR

Albumin-Creatinine Ratio (ACR)

Urine Protein Biomarkers

Renal Histopathology

Experience with pathways including:

TGF-? Signalling

Fibrotic Pathways

Inflammatory Cytokine Signalling

Complement Biology

Kidney Repair Mechanisms

Metabolic-Renal Pathways

Client-facing scientific leadership within a CRO environment

Project or line management experience

Why Apply?

Lead cutting-edge nephrology and renal drug discovery programmes

Work on novel therapies targeting CKD, AKI, renal fibrosis and progressive kidney disease

Influence strategic scientific decisions across multiple programmes

Collaborate with leading biotech and pharmaceutical organisations

Join a highly collaborative, research-driven environment with strong opportunities for scientific and leadership progression

If you are having difficulty in applying or if you have any questions, please contact Neil Walton at (url removed).

If you are interested in applying to this exciting opportunity, then please click 'Apply' or to speak to one of our specialists please request a call back at the top of this page.

Proclinical is a leading life sciences recruiter focused on finding exceptional people and matching them with the finest positions across the globe. Proclinical is acting as an Employment Agency in relation to this vacancy.

By submitting this application, you confirm that you've read and understood our privacy policy, which informs you how we process and safeguard your data

Related Jobs

View all jobs

Principal Scientist, Immunogenicity and Ligand Binding Assays

Moderna Oxford, United Kingdom
Hybrid

Principal Scientist, Immunogenicity and Ligand Binding Assays

Hybrid

Analytical Chemistry - Platform and Mass Spectrometry principal scientist

GSK Stevenage, United Kingdom
On-site

Immunohistochemistry Scientist

RBW Consulting Royston, Hertfordshire, United Kingdom
On-site

Translational Medicine Expert – Dermatology, Associate Director

Novartis London, United Kingdom
£67,900 – £126,100 pa Hybrid

Global Development Lead, Internal Medicine, Sr. Director (MD)

Pfizer England
On-site

Industry Insights

Discover insightful articles, industry insights, expert tips, and curated resources.